The FDA granted Merck's (NYSE: MRK) Isentress™ (raltegravir) accelerated approval for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. It is the first in a new class of drugs, which work to prevent HIV from inserting its DNA into human DNA, thereby inhibiting its ability to replicate and infect new cells. Merck has set the price for its newly approved AIDS drug Isentress at $27 a day wholesale, in the range of other popular medicines but lower than some at the highest end.
No comments:
Post a Comment